Barclays’s Pacira BioSciences PCRX Stock Holding History

Barclays’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-100	Closed	-$4K	–	6695
2019 Q3	$4K	Sell	100 -900	-90%	-$35.9K	﹤0.01%	6483
2019 Q2	$43K	Buy	+1,000	New	+$42.5K	﹤0.01%	6169
2018 Q4	–	Sell	-500	Closed	-$25K	–	7230
2018 Q3	$25K	Hold	500	–	–	﹤0.01%	6399
2018 Q2	$16K	Sell	500 -164,500	-100%	-$5.68M	﹤0.01%	6304
2018 Q1	$5.14M	Buy	165,000 +139,800	+555%	+$4.98M	﹤0.01%	1619
2017 Q4	$1.15M	Sell	25,200 -82,700	-77%	-$3.28M	﹤0.01%	2979
2017 Q3	$4.05M	Buy	107,900 +106,700	+8,892%	+$4.29M	﹤0.01%	1701
2017 Q2	$57K	Sell	1,200 -4,300	-78%	-$200K	﹤0.01%	5275
2017 Q1	$251K	Buy	+5,500	New	+$238K	﹤0.01%	4088
2015 Q3	–	Sell	-53,900	Closed	-$3.77M	–	6985
2015 Q2	$3.77M	Buy	+53,900	New	+$4.24M	﹤0.01%	1722
2014 Q3	–	Sell	-2,000	Closed	-$182K	–	7776
2014 Q2	$182K	Hold	2,000	–	–	﹤0.01%	4907
2014 Q1	$138K	Buy	+2,000	New	+$136K	﹤0.01%	5148
2013 Q3	–	Sell	-10,800	Closed	-$313K	–	7553
2013 Q2	$313K	Buy	+10,800	New	+$312K	﹤0.01%	4735

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's PCRX Position: Q2 2026 in Review

Barclays increased its Pacira BioSciences (PCRX) stake by 10% in Q2 2026, buying an estimated $664K and bringing the position to 310,189 shares worth $7.87M. The position accounts for ﹤0.01% of the portfolio, ranked #1601.

Barclays first reported a position in PCRX in Q2 2013 and has held it in 53 quarters since. The position peaked at $12.3M in Q1 2017. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Barclays held 310,189 shares of Pacira BioSciences worth $7.87M as of Q2 2026.
Barclays bought 28,081 Pacira BioSciences shares in Q2 2026, an estimated $664K.
Pacira BioSciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1601 holding.
Barclays first reported a position in Pacira BioSciences in Q2 2013 and has held it in 53 quarters since.
Barclays's Pacira BioSciences position peaked at $12.3M in Q1 2017.
254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.